Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-22T17:34:04.542Z Has data issue: false hasContentIssue false
  • English
  • Français

A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy

Published online by Cambridge University Press:  01 January 2021

Frazer A. Tessema  and
Jonathan J. Darrow
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Health Policy Portal
Information
Journal of Law, Medicine & Ethics , Volume 45 , Issue 4: Stigma & Health , Winter 2017 , pp. 692 - 697
Copyright
Copyright © American Society of Law, Medicine and Ethics 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

U.S. Food and Drug Administration News Release, “FDA News Release: FDA Approval Brings First Gene Therapy to the United States,” FDA, August 30, 2017, available at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Novartis, “Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Adult Patients with r/r DLBCL,” April 18, 2017, available at <https://www.novartis.com/news/media-releases/novartis-cart-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation> (last visited Nov. 30, 2017); U.S. Food and Drug Administration, Transcript for the July 12, 2017 Meeting of the Oncologic Drugs Advisory Committee (ODAC) (PM Session), July 12, 2017, at 136-140, available at <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM573721.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+U.S.+Food+and+Drug+Administration,+Transcript+for+the+July+12,+2017+Meeting+of+the+Oncologic+Drugs+Advisory+Committee+(ODAC)+(PM+Session),+July+12,+2017,+at+136-140,+available+at++(last+visited+Nov.+30,+2017).>Google Scholar
Stein, R., “‘Living Drug’ That Fights Cancer By Harnessing Immune System Clears Key Hurdle,” National Public Radio, July 12, 2017, available at <http://www.npr.org/sections/health-shots/2017/07/12/536812206/living-drug-that-fights-cancer-by-harnessing-the-immune-system-clears-key-hurdle> (last visited Nov. 30, 2017); See U.S. Food and Drug Administration, supra note 2, at 137.Google Scholar
See U.S. Food and Drug Administration News Release, supra note 1.Google Scholar
See U.S. Food and Drug Administration News Release, supra note 1.Google Scholar
ClinicalTrials.gov, “Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA),” available at <https://clinicaltrials.gov/ct2/show/NCT02435849> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
U.S. Food and Drug Administration, FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting, BLA 125646:Tisagenlecleucel, Novartis Pharmaceuticals Corporation, at 43, available at <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
See U.S. Food and Drug Administration, supra note 7, at 16.Google Scholar
Lee, D. W., et al., “Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome,” Blood 124, no. 2 (2014): 188-195, at 191.CrossRefGoogle Scholar
O’Leary, M., U.S. Food & Drug Administration Clinical Presentation: BLA125646, Tisagenlecleucel, Novartis Pharmaceuticals Corporation, July 12, 2017, at 23, available at <https://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM567383.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
See O’Leary, supra note 10, at 23.Google Scholar
See O’Leary, supra note 10, at 24.Google Scholar
See U.S. Food and Drug Administration, supra note 1.Google Scholar
Lash, A., “After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy,” Exome, March 1, 2017, available at <http://www.xconomy.com/seattle/2017/03/01/after-trial-deaths-juno-pivots-and-scraps-lead-car-t-therapy/#> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Brozak, S., “Gilead-Kite: A New Transformative Deal for Biotech,” Forbes, August 30, 2017, available at <https://www.forbes.com/sites/stephenbrozak/2017/08/30/gilead-kite-a-new-transformative-deal-and-maybe-the-new-future-of-healthcare-deals/#3269e0165d49> (last visited Nov. 30, 2017); Business Wire, “Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting,” Business Wire, April 2, 2017, available at <http://www.businesswire.com/news/home/20170402005096/en/Kite-Presents-Ongoing-Response-Rate-Plenary-Session> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+Business+Wire,+“Kite+Presents+Ongoing+Response+Rate+in+Plenary+Session+from+its+Pivotal+CAR-T+Trial+of+Axicabtagene+Ciloleucel+in+Patients+with+Aggressive+Non-Hodgkin+Lymphoma+at+the+2017+American+Association+of+Cancer+Research+Annual+Meeting,”+Business+Wire,+April+2,+2017,+available+at++(last+visited+Nov.+30,+2017).>Google Scholar
Novartis Press Release, “Novartis Receives First Ever FDA Approval for a CAR-T Cell Therapy, Kymriah(TM) (CTL019), for Children and Young Adults with B-cell ALL that is Refractory or has Relapsed at Least Twice,” August 30, 2017, available at <https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019> (last visited Nov. 30, 2017); Broderick, J. M., “FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy,” OncLive, August 30, 2017, available at <http://www.onclive.com/web-exclusives/fda-oks-tisagenlecleucel-in-allas-first-approved-car-tcell-therapy> (last visited No. 30, 2017).+(last+visited+Nov.+30,+2017);+Broderick,+J.+M.,+“FDA+OKs+Tisagenlecleucel+in+ALL+as+First+Approved+CAR+T-Cell+Therapy,”+OncLive,+August+30,+2017,+available+at++(last+visited+No.+30,+2017).>Google Scholar
Grady, D., “F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment,” New York Times, July 12, 2017, available at <https://www.nytimes.com/2017/07/12/health/fda-novartis-leukemia-gene-medicine.html?_r=0> (last visited Nov. 30, 2017); Mukherjee, S., “FDA Panel Backs Groundbreaking Novartis Treatment That Turns Your Cells Into Cancer Killers,” Fortune, July 12, 2017, available at < http://fortune.com/2017/07/12/fda-novartis-car-t-cancer-treatment/> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+Mukherjee,+S.,+“FDA+Panel+Backs+Groundbreaking+Novartis+Treatment+That+Turns+Your+Cells+Into+Cancer+Killers,”+Fortune,+July+12,+2017,+available+at+<+http://fortune.com/2017/07/12/fda-novartis-car-t-cancer-treatment/>+(last+visited+Nov.+30,+2017).>Google Scholar
Roland, D. and Loftus, P., “FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag,” Wall Street Journal, August 30, 2017, available at <https://www.wsj.com/articles/fda-approves-first-gene-therapy-in-us-1504108512> (last visited September 7, 2017).+(last+visited+September+7,+2017).>Google Scholar
Patients for Affordable Drugs Press Release, “Statement From Patients For Affordable Drugs On Novartis’ Drug Price,” Patients For Affordable Drugs, August 30, 2017, available at <http://www.patientsforaffordable-drugs.org/2017/08/30/statement-from-patients-for-affordable-drugs-on-novartis-drug-price/> (last visited Nov. 30, 2017); Weintraub, A., “Novartis CEO Opens Door to Cancer Patient Demanding ‘Fair’ CAR-T Pricing,” FiercePharma, August 21, 2017, available at <http://www.fiercepharma.com/financials/patient-advocacy-group-demands-fair-car-t-pricing-from-novartis> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+Weintraub,+A.,+“Novartis+CEO+Opens+Door+to+Cancer+Patient+Demanding+‘Fair’+CAR-T+Pricing,”+FiercePharma,+August+21,+2017,+available+at++(last+visited+Nov.+30,+2017).>Google Scholar
See Novartis Press Release, supra note 16.Google Scholar
See Novartis Press Release, supra note 16.Google Scholar
Kaltenboeck, A. and Bach, P. B., “Outcomes-Based Drug Contracts Do Not Move Us Closer to Value,” Morning Consult, June 21, 2017, available at <https://morningconsult.com/opinions/outcomes-based-drug-contracts-not-move-us-closer-value/> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Berkrot, B., “Novartis Gene Therapy Approval Signals New Cancer Treatment Era,” Reuters, August 30, 2017, available at <https://www.reuters.com/article/us-novartis-fda/novartis-gene-therapy-approval-signals-new-cancer-treatment-era-idUSKCN1BA-1ZY> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Novartis Press Release, “Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Adult Patients with r/r DLBCL,” Novartis, April 18, 2017, available at <https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Experts in Chronic Myeloid Leukemia, “The Price of Drugs for Chronic Myeloid Leukemia (CML) is a Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Larger Group of CML Experts,” Blood 121, no. 22 (2013): 4439-4442, at 4440; Pazdur, R., Letter to Robert A. Miranda, Associate Director Drug Regulatory Affairs at Novartis Pharmaceuticals Corporation, 2001, available at <https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21335s001ltr.pdf> (last visited Nov. 30, 2017).Google Scholar
Tversky, A. and Kahneman, D., “Judgement under Uncertainty: Heuristics and Biases,” Science 185, no. 4157 (1974): 1124-1131, at 1129.CrossRefGoogle Scholar
21 U.S.C. § 360ff (2016).Google Scholar
Gaffney, A., RAC, Mezher, M., Brennan, Z., “Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers,” Regulatory Affairs Professionals Society, August 30, 2017, available at <http://www.raps.org/Regulatory-Focus/News/2015/07/02/21722/Regulatory-Explainer-Everything-You-Need-to-Know-About-FDA%E2%80%99s-Priority-Review-Vouchers/> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
National Cancer Institute, NCI Guidelines For Investigators: Adverse Event Reporting Requirements For DCTD (CTEP and CIP) and DCP INDs A IDEs, March 28, 2011, at 22-23, available at <https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines3-29-11.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Bryan, W. W., “Letter to Dr. Patel on STN: BL 125646/0,” August 30, 2017, available at <https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Brennan, Z., “‘Historic Action’: FDA Approves First CAR-T Therapy,” Regulatory Affairs Professionals Society, August 30, 2017, available at <http://raps.org/Regulatory-Focus/News/2017/08/30/28367/Historic-Action-FDA-Approves-First-CAR-T-Therapy/> (last visited Nov. 30, 2017)+(last+visited+Nov.+30,+2017)>Google Scholar
X. Lin, Statistical Review, Biologics License Application 125646/0, U.S. Food and Drug Administration, at 24, available at <https://www.fda.gov/BiologicsBloodVaccines/CellularGene-TherapyProducts/ApprovedProducts/ucm573706.htm>; see ClinicalTrials.gov, supra note 5.;+see+ClinicalTrials.gov,+supra+note+5.>Google Scholar
See U.S. Food and Drug Administration, supra note 7, at 40; see Clinical-Trials.gov, supra note 6.Google Scholar